Title:
Cancer Nanotechnology Platform Development (R01) (RFA)

Contact:

Greg Downing, D.O., Ph.D.
Director, Office of Technology and Industrial Relations
Office of the Director, NCI
Telephone: (301) 496-1550
E-mail: downingg@mail.nih.gov

Objective of Project:

As part of the NCI Alliance for Nanotechnology in Cancer, this Request for Applications (RFA) aims to support investigator-initiated research projects in basic, applied, or translational areas that use nanotechnology to accelerate the diagnosis, treatment, and prevention of cancer, with a particular focus on targeted technology development efforts in molecular imaging and early detection, in vivo imaging, reporters of treatment efficacy, multifunctional therapeutics, cancer prevention and control, and research enablers. Researchers will generally be expected to collaborate as members of multidisciplinary research teams with one or more NCI Centers of Cancer Nanotechnology Excellence.

Description of Project:

Based on input from the Cancer Nanotechnology Plan and from the Request for Information (RFI), “Creating Cancer Nanotechnology Platforms through Directed Research Programs” (NOT-CA-04-022), the NCI will support specific, targeted nanotechnology platform development for cancer research and clinical application. Individual researchers will be supported by an R01 mechanism via Bioengineering Research Partnerships (BRPs) and Bioengineering Research Grants (BRGs). The BRPs will fund basic, applied, and translational nanotechnology research that applies an integrative, systems approach to develop knowledge and/or methods to prevent, detect, diagnose, or treat cancer. The BRG awards support multidisciplinary research performed in a single laboratory or by a small number of investigators that applies an integrative, systems approach to develop knowledge and/or methods to prevent, detect, diagnose, or treat disease or to understand health and behavior. A BRG application may propose hypothesis-driven, discovery-driven, developmental, or design-directed research at universities, national laboratories, medical schools, large or small businesses, or other public and private entities.